Drugs / MMR vaccine
MMR vaccine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | M-M-RVaxPro | — | 2006-05-05 | europa.eu ↗ |
Trials 13 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 9 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03101111 Comparator | Aug 2017 → Apr 2019 | chikungunya | Themis Bioscience GmbH | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07103148 Background | Jul 2025 → Aug 2026 overdue | yellow fever | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT06975878 Background | May 2025 → Aug 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06806137 Background | May 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06740630 Background | Jan 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT03853785 Comparator | Feb 2020 → Feb 2021 | anogenital human papillomavirus infection | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT01839175 Background | Apr 2013 → Jul 2014 | meningococcal infection, viral infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01553279 Background | Mar 2012 → Sep 2013 | meningococcal infection, viral infectious disease | MCM Vaccines B.V. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06257212 Comparator | Feb 2024 → Aug 2025 | chronic obstructive pulmonary disease | Josefin Eklöf | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMR vaccine | “An additional group with participants of 11-15 months of age will also receive at the same vaccination visit vYF and a single dose of MMR vaccine.” NCT07103148 ↗17“Eligible children in Group 2 will receive a standard dose (0.5 ml) of MMR vaccine during the first medical visit (V1).” NCT01770119 ↗ “the MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.” NCT04111432 ↗ “MMR vaccine administered on Day 0 and yellow fever vaccine administered on Day 28.” NCT03368495 ↗ |
| Known as | M-M-RvaxPro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06975878 ↗ |
| Known as | measles mumps, and rubella combined live attenuated vaccine | “measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml)” NCT04111432 ↗ |
| Known as | Measles, Mumps, Rubella (MMR) vaccine | “randomized control clinical trial with the live attenuated Measles, Mumps, Rubella (MMR) vaccine in healthcare workers in the greater New Orleans area” PMID 37153751 ↗ Feb 2023 |
| Known as | MMR (TV) | “MMR (TV) combined measles, mumps and rubella vaccine produced in Bio-Manguinhos” NCT01777529 ↗ |
| Known as | MMR-II | “Merck MMR-II vaccine” NCT04475081 ↗ |
| Known as | Mumps, measles and rubella (MMR) vaccine | “Mumps, measles and rubella (MMR) vaccine is a freeze-dried preparation of live attenuated strains of measles, mumps and rubella viruses” NCT03853785 ↗ |
| Modality | Vaccine | “Measles, mumps, and rubella vaccine (live)” NCT01553279 ↗ |
| Route | Intramuscular | “given via 0.5 mL intramuscular injection” NCT01553279 ↗ |